Display options
Cite
Ferdowsi S, Ghaffari SH, Amirizadeh N, et al. JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. Int J Hematol Oncol Stem Cell Res. 2016;10(2):70-8
Ferdowsi, S., Ghaffari, S. H., Amirizadeh, N., Azarkeivan, A., Atarodi, K., Faranoush, M., Toogeh, G., Shirkoohi, R., Vaezi, M., Maghsoodlu, M., Alimoghaddam, K., Ghavamzadeh, A., & Teimori Naghadeh, H. (2016). JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. International journal of hematology-oncology and stem cell research, 10(2), 70-8.
Ferdowsi, Shirin, et al. "JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden." International journal of hematology-oncology and stem cell research vol. 10,2 (2016): 70-8.
Ferdowsi S, Ghaffari SH, Amirizadeh N, Azarkeivan A, Atarodi K, Faranoush M, Toogeh G, Shirkoohi R, Vaezi M, Maghsoodlu M, Alimoghaddam K, Ghavamzadeh A, Teimori Naghadeh H. JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. Int J Hematol Oncol Stem Cell Res. 2016 Apr 01;10(2):70-8. PMID: 27252806; PMCID: PMC4888151.
Copy Download .nbib Format: NLM
Share it on

Int J Hematol Oncol Stem Cell Res. 2016 Apr 01;10(2):70-8.

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.

International journal of hematology-oncology and stem cell research

Shirin Ferdowsi, Seyed H Ghaffari, Naser Amirizadeh, Azita Azarkeivan, Kamran Atarodi, Mohammad Faranoush, Gholamreza Toogeh, Reza Shirkoohi, Mohammad Vaezi, Mahtab Maghsoodlu, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Hosein Teimori Naghadeh

Affiliations

  1. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  2. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  3. Hematology-Oncology and BMT Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  4. Molecular Genetics, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 27252806 PMCID: PMC4888151

Abstract

BACKGROUND: Myeloproliferative neoplasms (MPNs) are clonal malignant diseases that represent a group of conditions including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The aim of this study was to evaluate possible correlations between JAK2V617F allele burden and clinicohematologic characteristics in Iranian patients with MPNs. We also aimed at determining the correlation between JAK2V617F allele burden and use of cyto reductive treatment (hydroxyurea).

MATERIALS AND METHODS: We performed ARMS-PCR for all MPNs samples and subsequently performed real-time quantitative polymerase chain reaction (qRT-PCR) for JAK2V617F allele burden measurement using DNA from peripheral blood leukocytes.

RESULTS: Two distinct groups of patients were examined at a single time point: group A (n=40; 20 PV, 20 ET) was examined at the time of diagnosis; group B (n=85; 40 PV, 30 ET and 15 PMF) while under treatment with hydroxyurea (HU). The median allele burden of the JAK2 V617F was 72% for PV and 49% for ET patients at the time of diagnosis (p=0.01). For patients with HU treatment, we determined the median JAK2V617F allele burden to be 43%, 40%, and 46.5 % in PV, ET and PMF patients; respectively. HU-treated PV patients had a significant lower %JAK2V617F than PV patients at the time of diagnosis (43% vs. 72%, p=0.005). In ET group, the relationship between the JAK2 V617F allele burden and leukocyte count was significant (p=0.02 and p=0.01 in untreated and treated patients, respectively).

CONCLUSIONS: Our results showed that patients with PV have a higher JAK2V617F allele burden. Moreover, our study demonstrated that the JAK2V617F allele burden correlates with clinical features in ET group. We also showed hydroxyurea can affect the JAK2V617F allele burden in PV patients.

Keywords: Hydroxyurea; JAK2V617F; Myeloproliferative neoplasms

References

  1. PLoS One. 2013;8(1):e52518 - PubMed
  2. Blood. 2005 Sep 15;106(6):2162-8 - PubMed
  3. Blood Res. 2013 Jun;48(2):128-32 - PubMed
  4. Cancer Cell. 2005 Apr;7(4):387-97 - PubMed
  5. Cancer. 2006 Feb 1;106(3):631-5 - PubMed
  6. Ann Hematol. 2014 Apr;93(4):609-16 - PubMed
  7. Haematologica. 2010 Jul;95(7):1090-7 - PubMed
  8. Leukemia. 2008 Jul;22(7):1299-307 - PubMed
  9. Haematologica. 2010 Aug;95(8):1435-8 - PubMed
  10. Blood. 2011 Aug 18;118(7):1723-35 - PubMed
  11. Haematologica. 2008 Nov;93(11):1723-7 - PubMed
  12. Semin Thromb Hemost. 1997;23(4):339-47 - PubMed
  13. J Biol Chem. 2005 Jun 17;280(24):22788-92 - PubMed
  14. Zhonghua Xue Ye Xue Za Zhi. 2009 May;30(5):321-5 - PubMed
  15. Blood. 2014 Mar 6;123(10):1544-51 - PubMed
  16. Ann Hematol. 2009 Jul;88(7):629-32 - PubMed
  17. Haematologica. 2008 Jan;93(1):41-8 - PubMed
  18. J Formos Med Assoc. 2012 Jan;111(1):34-40 - PubMed
  19. Mol Biol Rep. 2012 Sep;39(9):8663-7 - PubMed
  20. Leukemia. 2006 Jun;20(6):1055-60 - PubMed
  21. Ann Hematol. 2014 May;93(5):791-6 - PubMed
  22. Leukemia. 2007 Sep;21(9):2074-5 - PubMed
  23. Leukemia. 2007 Sep;21(9):1952-9 - PubMed
  24. Haematologica. 2012 Apr;97(4):538-42 - PubMed
  25. Blood. 2007 Aug 1;110(3):840-6 - PubMed
  26. Eur J Haematol. 2007 Dec;79(6):508-15 - PubMed
  27. Leukemia. 2010 Jun;24(6):1128-38 - PubMed
  28. Br J Haematol. 2011 Feb;152(4):413-9 - PubMed
  29. Int J Hematol. 2014;99(5):625-34 - PubMed
  30. Indian J Med Res. 2010 Oct;132:423-7 - PubMed
  31. Lancet. 2005 Mar 19-25;365(9464):1054-61 - PubMed
  32. CA Cancer J Clin. 2009 May-Jun;59(3):171-91 - PubMed
  33. Leuk Res. 2011 Feb;35(2):177-82 - PubMed
  34. Leukemia. 2010 Sep;24(9):1574-9 - PubMed
  35. Exp Hematol. 2009 Oct;37(10):1186-1193.e7 - PubMed
  36. Clin Ter. 2012;163(2):109-13 - PubMed
  37. Nature. 2005 Apr 28;434(7037):1144-8 - PubMed
  38. Cancer. 2007 Jun 1;109(11):2279-84 - PubMed
  39. Hematology. 2009 Feb;14 (1):11-5 - PubMed
  40. Haematologica. 2011 Mar;96(3):e18-20 - PubMed
  41. Haematologica. 2008 Aug;93(8):1260-1 - PubMed
  42. Genet Test Mol Biomarkers. 2012 Jul;16(7):802-5 - PubMed
  43. Genet Test Mol Biomarkers. 2011 Apr;15(4):263-5 - PubMed
  44. Ann Lab Med. 2012 Nov;32(6):385-91 - PubMed
  45. PLoS One. 2013;8(2):e57856 - PubMed

Publication Types